(Press-News.org) ANN ARBOR, Michigan — A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.
High-grade serous carcinoma, the most common type of ovarian cancer, usually begins in the fallopian tube, before spreading to the ovaries and other pelvic organs. The cancer is typically discovered at an advanced stage and becomes resistant to current chemotherapies. Its underlying genetics are complex, with multiple genetic alterations and instabilities. One of the genes involved is CDK12.
In this new study, published in the Proceedings of the National Academy of Sciences, researchers from the University of Michigan Rogel Cancer Center report on a new mouse model that shows CDK12 acts as a tumor suppressor to drive high-grade serous carcinoma arising in the mouse oviduct – the equivalent of human fallopian tube. A promising degrader targeting CDK12 and a related gene, CDK13, can destroy these tumors.
“This is the first demonstration of in a mouse model that CDK12 plays a tumor suppressor role in this type of cancer. When we inactivate CDK12, tumors grow a lot faster and the mice die sooner, showing that this is a more aggressive form of the disease,” said co-senior study author Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at Michigan Medicine.
The mouse model used in this work was crucial to the discovery. It was based on a genetically engineered model previously created by Kathleen R. Cho, M.D., in which three genes known to suppress the development of high-grade serous carcinoma were deleted in the mouse oviduct. Here, CDK12 was added for a quadruple inactivation of genes.
“It is very important to credential the model systems by showing they recapitulate key features of their human counterparts, a process that is also very time-consuming,” said co-senior study author Cho, Peter A. Ward Professor of Pathology, co-director of the Rogel Cancer Center’s cancer genetics program, and director of gynecologic pathology at Michigan Medicine.
“These features include not only cell of origin and appearance under the microscope, but also timing of tumor development, underlying genetics, acquired genetic alterations and gene expression profiles, tumor microenvironment (including the immune cell components) and other aspects of biological behavior,” she said.
The result here enabled researchers to see that in addition to fueling aggressive tumor growth, inactivating CDK12 triggered an immune cell response, recruiting immune T cells to the tumor. Further, researchers identified a partner gene, CDK13, as a target for a degrader or inhibitor of CDK12. A CDK12/13 degrader along with immune checkpoint inhibitors in the mouse model led to reduced tumor growth, suggesting a combination therapy could be effective in this subset of ovarian cancers.
“While there have been some improvements in the management of high-grade serous carcinoma, once patients become resistant to first-line chemotherapy, selection of other chemotherapeutic agents is largely guesswork. New treatments are sorely needed, as the overall survival of women with this cancer type remains quite poor,” Cho said.
Chinnaiyan’s team previously reported on similar findings in prostate cancer, demonstrating CDK12 as a key driver of aggressive disease. CDK12 is known to play a role in about 7% of metastatic prostate cancers and about 3% of tubo-ovarian high-grade serous cancers. It has not been shown to be inactivated in other cancer types.
“The types of therapies that might be tried in ovarian cancer are different than prostate cancer. Here, we bring the two diseases together and show that CDK12/13 inhibitors or degraders should be considered in both these cancer types,” Chinnaiyan said.
Several CDK12/13 inhibitors are in development, including the compound the U-M team developed. Researchers plan to further develop the CDK12/13 degrader with a goal of moving it to a clinical trial.
Note for patients: This work is preclinical and more research is needed. A CDK12/13 degrader is not currently available in clinical trials. For information on current clinical trials or questions about ovarian cancer treatment, call the Michigan Medicine Cancer AnswerLine at 800-865-1125 or visit www.rogelcancercenter.org/clinical-trials.
Additional authors: Jean Ching-Yi Tien, Yali Zhai, Rong Wu, Yuping Zhang, Yu Chang, Yunhui Cheng, Abigail J. Todd, Christina E. Wheeler, Shuqin Li, Rahul Mannan, Caleb Cheng, Brian Magnuson, Gabriel Cruz, Yizhi Cao, Somnath Mahapatra, Xuhong Cao, Fengyun Su, Rui Wang, Jianzhang Yang, Licheng Zhou, Yuanyuan Qiao, Lanbo Xiao, Marcin Cieslik, Xiaoju Wang, Zhen Wang, Jonathan Chou, Ke Ding
Funding for this work is from National Cancer Institute grants P50-CA186786, U2C-CA271854, R35-CA231996; National Natural Science Foundation of China; Department of Defense grant W81XWH-21-1-0458; Prostate Cancer Foundation.
Disclosure: Patents for CDK12/13 degraders/inhibitors used here have been filed by the University of Michigan and Shanghai Institute of Organic Chemistry, with Chinnaiyan, King, X. Wang, Y. Chang and Tien as co-inventors
Paper cited: “Defining CDK12 as a Tumor Suppressor and Therapeutic Target in Mouse Models of High-Grade Serous Carcinoma,” PNAS. DOI: 10.1073/pnas.2426909122
Resources:
University of Michigan Rogel Cancer Center, www.rogelcancercenter.org
Michigan Medicine Cancer AnswerLine, 800-865-1125
# # #
END
Deep in the swamps of the American Southeast stands a quiet giant: the bald cypress (Taxodium distichum). These majestic trees, with their knobby “knees” and towering trunks, are more than just swamp dwellers – they’re some of the oldest living organisms in Eastern North America. Some have been around for more than 2,500 years, quietly thriving in nutrient-poor, flooded forests where most other trees would wither.
But life isn’t easy for these ancient trees. They’re under siege ...
The inaccuracy of race and ethnicity data found in electronic health records (EHRs) can negatively impact patient care as artificial intelligence (AI) is increasingly integrated into healthcare. Because hospitals and providers inconsistently collect such data and struggle to accurately classify individual patients, AI systems trained on these datasets can inherit and perpetuate racial bias.
In a new publication in PLOS Digital Health, experts in bioethics and law call for immediate standardization of methods for collection of race and ethnicity data, and for developers to warranty race and ethnicity data quality in medical AI systems. The research synthesizes concerns about why patient ...
HOUSTON – (June 9, 2025) – Researchers at Rice University have developed a soft robotic arm capable of performing complex tasks such as navigating around an obstacle or hitting a ball, guided and powered remotely by laser beams without any onboard electronics or wiring. The research could inform new ways to control implantable surgical devices or industrial machines that need to handle delicate objects.
In a proof-of-concept study that integrates smart materials, machine learning and an optical control system, a team of Rice researchers led by materials scientist Hanyu Zhu used a light-patterning device to ...
Investigative journalists are facing severe challenges and threats, and their vital connections with whistleblowers are under increasing pressure, researchers have said.
Legal intimidation is having a "chilling effect" and those engaged in crime and security journalism are encountering extreme risks.
Experts have discussed their significant concerns about the perils many journalists face in their commitment to uncovering truth, from pervasive state surveillance to targeted prosecution and even espionage ...
ANN ARBOR, Michigan — As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds light on whether patients are opting for it.
In a study of 591 women with early stage breast cancer who completed five years of endocrine therapy, 47% decided to continue the treatment. Patients with stage 2 disease were more likely to continue, with 62% agreeing, compared to 39% of patients with stage 1 cancer.
The study, led by researchers at the University of Michigan Rogel Cancer Center and Stanford Medicine, was published in the Journal of the National Cancer Institute.
Endocrine ...
The Center for Bioenergy Innovation, or CBI, at the Department of Energy’s Oak Ridge National Laboratory has promoted Melissa Cregger and Carrie Eckert to serve as chief science officers, advancing the center’s mission of innovations for new domestic biofuels, chemicals and materials.
Cregger will oversee CBI’s development of resilient, high-yielding, non-food feedstock crops, while Eckert will guide the center’s research on cost-effective methods to break down and convert plant biomass into valuable fuels and products.
Brian Davison, chief scientist for biotechnology at ORNL and formerly chief science officer for the center, ...
Recent scholarship has concluded that Neanderthals made a second major migration from Eastern Europe to Central and Eastern Eurasia between 120,000 and 60,000 years ago. But the routes they took have long been a mystery—primarily because there are few archaeological sites connecting the two regions.
In a new analysis, a team of anthropologists—using computer simulations—has offered a map of possible pathways, which concludes Neanderthals likely used river valleys as natural highways and traveled during warmer periods to move approximately 2,000 miles (3,250 km) in less than 2,000 years.
“Our findings show that, despite obstacles like mountains ...
A new study from The University of Texas at Arlington details a novel strategy for how the body clears out dead cells during stress, revealing unexpected roles for well-known stress-response genes—a discovery that could help scientists better understand diseases affecting the immune system, brain and metabolism.
“The body is constantly creating new cells and removing old cells once they die,” said Aladin Elkhalil, lead author of the study and a third-year doctoral student in the lab of Piya Ghose, ...
DARIEN, IL – A new study to be presented at the SLEEP 2025 annual meeting found that teens with earlier, more efficient, and less variable sleep patterns at age 15 had better cardiovascular health at age 22.
Results show that several healthy sleep habits at age 15 predicted a higher (better) cardiovascular health score at age 22: falling asleep and waking up earlier, spending a lower percentage of time in bed awake, and having lower variability in total sleep time and sleep onset. In contrast, average total sleep time did not predict future cardiovascular health. Results were adjusted for potential confounders ...
Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we now call precision oncology, characterizing the molecular features of a patient's specific cancer to determine the most effective treatment.
Prostate cancer is considered the most prevalent tumor among men, and it typically has a high cure rate. As such, although many men will be diagnosed with this cancer, the majority will be cured. "However, when we refer ...
